CEO Transition and Earnings Miss
LifeVantage Withholds FY27 Outlook Amid CEO Transition and Declining Revenue
Anonymous
Key Points
1
LifeVantage plans not to issue a fiscal 2027 outlook due to the ongoing CEO transition.
2
CEO Terrence Moorehead emphasized the company’s foundation, noting a debt-free balance sheet and strong gross margins alongside a differentiated, science-backed platform.
3
In the fourth quarter, LifeVantage reported earnings per diluted share of $0.11, missing the consensus estimate by $0.01.
4
The quarterly dividend remains $0.05 per share, with an ex-dividend date of Sept. 1 and an annualized payout of $0.20 (yield about 3.1%).
5
LifeVantage stock traded lower on the results, with shares down roughly $0.16 to $6.45 on the day, alongside mentioned trading volume and reference to major moving averages.
LifeVantage Corporation reported weaker fourth quarter and full-year 2026 results, with revenue sliding 23.1% to $42.4 million due to fewer orders and smaller order sizes. Yahoo Finance The company will not issue a 2027 outlook during its ongoing CEO transition, leaving investors uncertain about the path forward as shares fell roughly $0.16 to $6.45.
CEO Terrence Moorehead framed the slump as part of a turnaround effort, emphasizing LifeVantage's debt-free balance sheet and science-backed platform. The company maintained its quarterly dividend at $0.05 per share, translating to a 3.1% yield, signaling confidence despite near-term headwinds.
Q4 Earnings Miss on Weak Demand
LifeVantage reported adjusted earnings per diluted share of $0.11 in the fourth quarter, missing the consensus estimate by $0.02, according to ScanX. The miss reflects deeper challenges: fewer customer orders, smaller average order sizes, and tough comparisons against last year's strong sales of its MindBody GLP-1 System, Watchlist News reported. Revenue fell in both the Americas and Asia/Pacific regions, dragging down the full-year performance.
No FY27 Guidance Amid Leadership Uncertainty
The company will withhold its formal 2027 outlook due to the CEO transition, according to Benzinga. LifeVantage has outlined only a capex target of $3-$3.5 million for fiscal 2027, Seeking Alpha noted. This lack of guidance removes a key signal investors use to assess momentum and leaves the company's strategic direction unclear until new leadership settles in.
Foundation Remains Intact Despite Revenue Slide
CEO Moorehead highlighted LifeVantage's strengths: a debt-free balance sheet, strong gross margins, and a differentiated science-backed platform. The company is pursuing three core priorities: strengthening the brand, refining its consumer proposition, and driving operational excellence. Despite the near-term pressure, management framed these fundamentals as the foundation for a successful turnaround.
Dividend Steady as Market Questions Outlook
LifeVantage maintained its quarterly dividend at $0.05 per share, with an ex-dividend date of September 1 and an annualized payout of $0.20. The steady dividend signals the board's confidence in cash generation, but it could also reflect a conservative approach during transition uncertainty. Stock investors reacted negatively, sending shares lower as the lack of forward guidance and earnings miss weighed on sentiment.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
37
Reach
49
A
AnonymousAuthor
